Metraipolis › archive › dc_82b7e62fdb68

Changes in evidence used for FDA Novel Drug Approvals: 2016-2024 — Europe PMC PMID:42647463

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42647463
DOI
10.1371/journal.pone.0342878
License (as archived)
solo-consultazione
Archived
2026-11-01T07:36:42.734Z
SHA-256 of the archived text
1cbd591715b275b4468f22e42e4ac390d96f3ce82b16317ae977c5175ce17307
Stable URL of this page
https://metraipolis.com/documento/dc_82b7e62fdb68

How to cite

Changes in evidence used for FDA Novel Drug Approvals: 2016-2024 — Europe PMC PMID:42647463 — Europe PMC (en), https://europepmc.org/article/MED/42647463 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_82b7e62fdb68 (Metraipolis archive dc_82b7e62fdb68, sha256 1cbd591715b275b4468f22e42e4ac390d96f3ce82b16317ae977c5175ce17307)
BibTeX
@misc{dc82b7e62fdb68,
  title = {Changes in evidence used for FDA Novel Drug Approvals: 2016-2024 — Europe PMC PMID:42647463},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42647463},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_82b7e62fdb68; sha256 1cbd591715b275b4468f22e42e4ac390d96f3ce82b16317ae977c5175ce17307},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42647463. Agents can read the archived copy with the MCP tool read_document.